Inventory destocking in commercial molecules
Two large commercial molecules are experiencing destocking, impacting pharma CDMO revenue growth. The destocking is expected to last the full year.
medium · management_commentaryCohance Lifesciences Limited — Q1 FY26
Cohance Life Sciences reported Q1 FY26 revenue growth of 13% YoY, with pharma CDMO growing over 30% excluding inventory destocking.
bullish
medium
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Tariff exposure on US exports
Potential US tariffs on pharma intermediates could impact exports, though management noted current FOB terms and customer willingness to absorb tariffs.
medium · analyst_questionOne-time expenses impacting EBITDA
Ongoing one-time expenses (ESOP, professional fees) are distorting EBITDA margins, with no clear timeline for normalization.
low · analyst_questionExecution risk in new capacity ramp-up
The oligonucleotide and bio-conjugation expansions are on schedule but any delays could impact revenue contribution from niche technologies.
low · data_observation